BEAM250117P25000
- 1.60
- +0.20+14.29%
Beam Therapeutics Newsroom
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Buys 116K Shares of Beam Therapeutics Today
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Ahead of Crucial Inflation Data
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $48
Analysts' Top Healthcare Picks: Stoke Therapeutics (STOK), Beam Therapeutics (BEAM)
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
William Blair Remains a Buy on Beam Therapeutics (BEAM)
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
Express News | Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024